
Tuesday June 2, FDA is set to rule on $Vyne Therapeutics Inc 's FMX103, as a treatment option for moderate-to-severe papulopustular rosacea.

All Comments
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.